REGN REGENERON PHARMACEUTICALS, INC.

Overview and Growth

REGENERON PHARMACEUTICALS, INC. generated $14.34B of revenue in fiscal 2025, with net income of $4.50B and an operating cash inflow of $4.98B. At $14.34B, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Compared with $14.20B in fiscal 2024, revenue recorded a 1.0% year-over-year increase. On a per-share basis, diluted EPS was $41.48, which connects the reported earnings outcome with the company’s diluted share count. Diluted EPS increased by 8.2% from $38.34 in fiscal 2024, showing how the earnings change reached shareholders on a per-share basis. Asset turnover was 0.35x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

The reported operating result was $3.58B, capturing profitability after direct costs and the operating expenses reflected in the statements. Relative to revenue, operating income represented 24.9%, showing how efficiently sales converted into operating profit. After all reported below-operating-line items, the company recorded net income of $4.50B for the fiscal year. Measured against reported revenue, net income produced a 31.4% margin after operating costs and the remaining recognized items. The earnings statement records $5.23B of pretax income, the profit base against which the reported tax provision can be assessed. Pretax income represented 36.5% of revenue, placing earnings before tax in the context of the company’s operating scale. Income tax expense totaled $725.80M, providing the reported tax component that separates pretax and after-tax earnings. The effective relationship between income tax and positive pretax income was 13.9%, without assuming a statutory-rate comparison. The relationship between net income and period-end equity was 14.4%, indicating the profitability achieved on book capital.

Liquidity and Capital Structure

At period end, the $40.56B asset base was financed through $9.30B of liabilities and $31.26B of equity. The near-term balance sheet paired $18.02B of current assets with $4.37B of current liabilities at the reporting date. At 4.13x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $3.12B, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 71.4%, excluding receivables and other current assets. Total debt was $1.99B, establishing the amount of borrowing carried within the company’s capital structure. The debt-to-equity relationship was 0.06x, showing how much debt the company carried for each unit of book equity. Debt represented 4.9% of total assets, placing borrowing in the context of the company’s full resource base. Relative to total assets, liabilities measured 22.9%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 7.7%, comparing reported cash and equivalents with the full positive asset balance. Total assets were 7.4% higher than fiscal 2024 assets of $37.76B, measuring the company’s own balance-sheet change.

Cash Flow and Earnings Quality

Cash flow from operations was $4.98B, a reported cash inflow that can be compared directly with net income and capital spending. The operating-cash-flow-to-net-income relationship was 1.11x, comparing cash generated by operations with the bottom-line earnings result. Capital spending was $898.40M, absorbing part of the cash generated from operations before free cash flow. Relative to operating cash flow, capital expenditures measured 18.0%, connecting investment intensity with the company’s cash-generation base. The combination of operating cash flow and capital spending produced $4.08B of positive free cash flow for the period. Free cash flow represented 28.4% of revenue, linking post-investment cash generation with the company’s operating scale. The free-cash-flow-to-assets relationship was 10.1%, comparing post-investment cash with the balance-sheet asset base.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.